Kukje Pharma Co (XKRX:002720) Total Liabilities : ₩75,999 Mil (As of Dec. 2024)

View and export this data going back to 1975. Start your Free Trial

What is Kukje Pharma Co Total Liabilities?

Kukje Pharma Co's Total Liabilities for the quarter that ended in Dec. 2024 was ₩75,999 Mil.

Kukje Pharma Co's quarterly Total Liabilities increased from Jun. 2024 (₩70,705.16 Mil) to Sep. 2024 (₩72,542.14 Mil) and increased from Sep. 2024 (₩72,542.14 Mil) to Dec. 2024 (₩75,999.40 Mil).

Kukje Pharma Co's annual Total Liabilities increased from Dec. 2022 (₩62,513.60 Mil) to Dec. 2023 (₩78,309.91 Mil) but then declined from Dec. 2023 (₩78,309.91 Mil) to Dec. 2024 (₩75,999.40 Mil).

Kukje Pharma Co Total Liabilities Historical Data

The historical data trend for Kukje Pharma Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kukje Pharma Co Total Liabilities Chart

Kukje Pharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

75,126.69

71,195.24

62,513.60

78,309.91

75,999.40

Kukje Pharma Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															78,309.91	76,067.17	70,705.16	72,542.14	75,999.40

Kukje Pharma Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Kukje Pharma Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28547.063	+	(27341.941	+	16346.033
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2464.359	+	1300)
	=	75,999

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	165547.574	-	89548.177
	=	75,999

Kukje Pharma Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28547.063	+	(27341.941	+	16346.033
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2464.359	+	1300)
	=	75,999

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	165547.574	-	89548.177
	=	75,999

Kukje Pharma Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Kukje Pharma Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Kukje Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kukje Pharma Co Ltd (XKRX:002720) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

96-8 Yatapiro, Bundang-Gu, Seongnam-si, Gyeonggi, KOR, 463-839

Website

http://www.kukjepharm.co.kr

Kukje Pharma Co Ltd engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products internationally. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, penicillins, quinolones, aminoglycosides, macrolides, antifungal and antiviral agents, and other antibiotics.

Kukje Pharma Co Headlines

No Headlines